Campbell, CA, August 21st, 2018 – Dark Horse Consulting, the leading consultancy specializing in cell and gene therapy product development, today announced its planned attendance and sponsorship of the 2018 Cell & Gene Meeting on the Mesa, scheduled for October 3-5 in La Jolla, CA.
“The Meeting on the Mesa is one of the premier events for the cell & gene therapy community, and we are proud to contribute as a silver sponsor,” said Anthony Davies, Founder and CEO of Dark Horse Consulting. “We are looking forward to hearing updates from the presenting companies, catching up with many of our clients, and making new connections at the Partnering Forum.”
Co-hosted by the Alliance for Regenerative Medicine and the Sanford Stem Cell Clinical Center at UC San Diego Health, the Cell & Gene Meeting on the Mesa is a three-day conference featuring presentations by leading companies in the space, a nationally recognized Scientific Symposium, and the industry’s premier annual Partnering Forum. These meetings bring together top decision-makers in the industry with researchers and clinical experts from around the globe, fostering key partnerships and advancing the industry to ultimately bring more cures to patients.
Top executives from Dark Horse Consulting will be in attendance throughout the entirety of the conference and are available for scheduled 1-on-1 meetings or impromptu meetings at their exhibition table or partnering suite during the Partnering Forum. The consulting group’s sponsorship will also provide a sponsored lunch for conference attendees on Day 1 of the meeting.
To schedule a meeting with Dark Horse Consulting at Meeting on the Mesa’s Partnering Forum, email directly at firstname.lastname@example.org, or visit the Partnering Forum website at meetingonthemesa.com/partnering.
About Dark Horse Consulting
Dark Horse Consulting specializes in the development of cell and gene therapy products. All of our consultants have deep cell and gene therapy industry experience, spanning diverse functions including process development, device development, manufacturing, quality, regulatory, program management, business development, strategy, and financing/investor relations. Many of our consultants also bring experience from adjacent more mature sectors, including traditional biologics, small molecules, medical devices, and management consulting. As a result, we deeply understand the unique challenges faced by cell and gene Therapy developers and are able to apply best practices from other industries to address the needs of our clients.